

Fax completed prior authorization request form to 855-799-2554 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

Aetna Better Health®

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned

Pharmacy Coverage Guidelines are available at www.aetnabetterhealth.com/florida/providers/provider-pharmacy

## Kalydeco-Orkambi-Symdeko-Trikafta

Pharmacy Prior Authorization Request Form Do not copy for future use. Forms are updated frequently. REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification to support diagnosis

REGORED. Office hotes, labs an	a moulour t	coting role	vant t	oroqu	001 01101	, mi	, mearoar j	uotint		0 04	pportai	ugiit	/010		
Member Information			2: 4												
Member Name (first & last):		Date of E	Birth:				Gender:			Fem		eight:			
Member ID:		City:					State:					Weight:			
Prescribing Provider Information	1														
Provider Name (first & last):	r: N			NPI# DEA#			DEA#								
Office Address:		City:					State:			Zip Code:					
Office Contact:		Office Phone					Office Fax:				p 000				
Office Contact.			Onc	e Prior	le				Oncer	-ax.					
<b>Dispensing Pharmacy Information</b>	n														
Pharmacy Name:	Pha	Pharmacy Phone: Pharm					Pharma	hacy Fax:							
<b>Requested Medication Information</b>	on														
□ Kalydeco □ Orkambi □ Symdeko □															
Medication request is NOT for compendia-supported diagnosis (c				Diagno	osis:				ICD	-10 (	Code:				
Are there any contraindications to f If yes, please specify:				□ Yes				New request							
Directions for Use:				Strength:			Do:			age Form:					
				Quantity: Da				Day Supply: Dura			ation of Therapy/Use:				
What medication(s) has the member <b>Turn-Around Time for Review</b>	er tried and t								4 1 - 1 - 1		1.1				141-
<ul> <li>Standard – (24 hours)</li> <li>Urgent – waiting 24 hours for a standard decision or ability to regain maximum function, you can a Signature:</li> </ul>													eaith,		
Clinical Information Does member have documented d	lognosio of (	Natio Fibro		afirmad	via (haa	lth o	anditiona' (	20	diaglar	rd	102	_	Vee		Na
													Yes		
Have baseline liver tests been completed AND then will be completed every 3 months the 1 <sup>st</sup> year 1 Was a baseline ophthalmic exam completed?							-			Yes		No			
Was a baseline ophthalmic exam completed?				NO	□ N//		completed						Yes		No
Kalydeco	onfirming pr	oconco of (		ETD m	utation?							_	Voc		No
Did member have genetic testing confirming presence of ONE CFTR mutation?										INU					
Orkambi Was member determined to be HOMOzygous for the F508del mutation in CFTR gene as confirmed by an FDA-							Yes		No						
approved CF mutation test?															
Is member HOMOzygous for the F508del mutation?	□ Yes	□ No	Does member have at least ONE mutation in CFTR gene, that is responsive to tezacaftor-ivacaftor, based on in vitro date AND/OR clinical evidence?					□ Ye	es		No				
CFTR mutations responsive to teza D579G, 711+3A $\rightarrow$ G, E831X, S945 and 3849+10kbC $\rightarrow$ T			P67L,	R74W,	D110E,	D11	10H, R1170	C, E19	3K, L20	)6W,					
Is members' genotype unknown?	□ Yes	□ No					tic fibrosis				Yes		No		N/A
□ Trikafta			1001 0		20000 p	000									
Is member HOMOzygous for the F							Yes		No						
Is members' genotype unknown?	□ Yes	□ No				-	tic fibrosis				Yes		No		
tive: 03/21/2020 C17970-A, C17971-A, C17972-A, C17968-A 01-2020 and 02-2020							ation?		Dec. (						
ctive: 03/21/2020 C17970-A, C17971-	ч, C17972-A	, C1/968-A	01-202	20 and (	JZ-2020						Page 1	ot 2			

Renewal Only									
Member experienced response by TWO or more of the following?			<ul> <li>Decreased pulmonary exacerbations compared to pretreatment baseline</li> <li>Improvement OR stabilization of lung function (as measured by % predicted</li> </ul>						
				<ol> <li>compared to baseline OR decrease in rate of decline ght gain</li> </ol>	, e. i.a.i.g		•		
			Improvement in patient symptoms as documented in clinical notes						
Did member receive lung transplant?	□ Yes		No	Did member experience unacceptable toxicity from requested medication?	ΟY		No		
Was annual follow-up ophthalmic exam completed?	□ Yes		No	Were annual LFTs completed?		es 🗆	No		
Additional information the prescribing p	orovider fee	ls is	impor	tant to this review. Please specify below or submit	medica	al record	ds.		
Signature affirms that information given on this form is true and accurate and reflects office notes.									
Prescribing Provider's Signature:				Date:					

## Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required

Standard turnaround time is 24 hours. You can call to check the status of a request.

Medicaid: 800-441-5501 Florida Healthy Kids: 844-528-5815

Effective: 03/21/2020 C17970-A, C17971-A, C17972-A, C17968-A 01-2020 and 02-2020